Why BlueJay Diagnostics Stock Is Falling
Why BlueJay Diagnostics Stock Is Falling
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares are trading lower Thursday after the company announced the pricing of a $3.5 million public offering.
Bluejay Diagnostics, Inc.（纳斯达克股票代码：BJDX）周四股价走低，此前该公司宣布了350万美元公开募股的定价。
The Details:
细节：
BlueJay Diagnostics announced the public offering of 2,692,308 shares at $1.30 per share. The gross proceeds from the offering are expected to be approximately $3.5 million, and BlueJay Diagnostics intends to use the proceeds to fund matters related to obtaining FDA approval, other research and development activities and for general working capital needs.
BlueJay Diagnostics宣布以每股1.30美元的价格公开发行2692,308股股票。此次发行的总收益预计约为350万美元，BlueJay Diagnostics打算将所得款项用于资助与获得美国食品药品管理局批准、其他研发活动以及一般营运资金需求有关的事项。
On Wednesday, the company announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients.
周三，该公司宣布启动一项多中心临床研究，以评估败血症患者的Symphony IL-6测试。
BlueJay Diagnostics shares are falling on heavy trading volume following the announcement of a public offering. According to data from Benzinga Pro, more than 447,000 shares have been traded in the session, compared to the stock's 100-day average of less than 26,000 shares.
宣布公开发行后，由于交易量庞大，BlueJay Diagnostics的股价正在下跌。根据Benzinga Pro的数据，该交易日已有超过44.7万股股票的交易，而该股的100天平均交易量不到26,000股。
BlueJay Diagnostics shares are trading below the stock's 50-day moving average of $3.29 and well-below its 52-week high of $17.60.
BlueJay Diagnostics的股票交易价格低于该股的50天移动平均线3.29美元，远低于其52周高点17.60美元。
Related News: Why Coherus BioSciences Stock Is Climbing Today
相关新闻：为什么 Coherus BioSciences 股票今天上涨
BJDX Price Action: According to Benzinga Pro, BlueJay Diagnostics shares are down 29% at $1.24 at the time of publication.
BJDX价格走势：根据Benzinga Pro的数据，BlueJay Diagnostics的股价在发布时下跌了29％，至1.24美元。
Image: Mohamed Hassan from Pixabay
图片：来自 Pixabay 的穆罕默德·哈桑